Agomab outlines Phase 2b trial design for Crohn's disease drug

June 23, 2026 4:05 PM

Agomab Therapeutics NV (Nasdaq: AGMB) has announced the design of its NOV-ERA Phase 2b study evaluating ontunisertib in patients with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found